0001209191-18-061387.txt : 20181206 0001209191-18-061387.hdr.sgml : 20181206 20181206181537 ACCESSION NUMBER: 0001209191-18-061387 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20181206 FILED AS OF DATE: 20181206 DATE AS OF CHANGE: 20181206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lichter Jay CENTRAL INDEX KEY: 0001376355 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38756 FILM NUMBER: 181221834 MAIL ADDRESS: STREET 1: C/O ARATANA THERAPEUTICS, INC. STREET 2: 11400 TOMAHAWK CREEK PARKWAY, SUITE 340 CITY: LEAWOOD STATE: KS ZIP: 66211 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Synthorx, Inc. CENTRAL INDEX KEY: 0001609727 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464709185 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11099 NORTH TORREY PINES ROAD, SUITE 290 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-750-4715 MAIL ADDRESS: STREET 1: 11099 NORTH TORREY PINES ROAD, SUITE 290 CITY: LA JOLLA STATE: CA ZIP: 92037 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-12-06 0 0001609727 Synthorx, Inc. THOR 0001376355 Lichter Jay C/O SYNTHORX, INC. 11099 N. TORREY PINES ROAD, SUITE 190 LA JOLLA CA 92037 1 0 1 0 Common Stock 187237 I By Avalon Ventues X, L.P. Series A Preferred Stock Common Stock 1281664 I By Avalon Ventures X, L.P. Series B Preferred Stock Common Stock 762617 I By Avalon Ventures X, L.P. Series C Preferred Stock Common Stock 3653909 I See Footnote The Reporting Person is a managing member of Avalon Ventures X GP LLC and Avalon Ventures X SPV GP LLC, the general partners of Avalon Ventures X, L.P. and Avalon X SPV, L.P., and shares voting and investment power with respect to the shares held by Avalon Ventures X, L.P. and Avalon X SPV, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon Ventures X, L.P. and Avalon X SPV, L.P., except to the extent of his actual pecuniary interest therein if any. The shares of Series A Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Series A Preferred Stock will automatically convert on a 1.60224-to-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to the 1.60224-to-1 reverse stock split of the Issuer's Common Stock effected on November 26, 2018, which will be effective for the Preferred Stock upon its conversion to Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Series B Preferred Stock will automatically convert on a 1.60224-to-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series C Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Series C Preferred Stock will automatically convert on a 1.60224-to-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering. The shares are held as follows: 2,517,278 shares held by Avalon Ventures X, L.P. and 1,136,631 shares held by Avalon X SPV, L.P. /s/ Christian V. Kuhlen, Attorney-in-Fact 2018-12-06 EX-24.3_819950 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Laura Shawver, Tighe Reardon and Christian V. Kuhlen of Synthorx, Inc. (the "Company"), signing individually, the undersigned's true and lawful attorney-in-fact and agent to: (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28th day of November, 2018. /s/ Jay Lichter